Product Strategy

Cristal Therapeutics is developing a product pipeline of next-generation targeted nanomedicines with a superior efficacy and tolerability offering multiple advantages for the patient. The company is internally focussing on oncology products and aims to set up co-development projects with partners in oncology and other disease areas. The CriPec® platform offers the possibility to rationally design optimal nanomedicine by selecting the right combination of the polymer and linker, dependent on the indication and type of drug. If even a higher level of selectivity is required, the CriPec nanomedicines can be modified with a targeting ligand.